STRUCTURE-BASED DEVELOPMENT OF INHIBITORS OF VIRAL CHYMOTRYPSIN-LIKE PROTEASES

基于结构的病毒胰凝乳蛋白酶样蛋白酶抑制剂的开发

• 批准号: 7370691
• 负责人: ERNST M BERGMANN
• 金额: $ 0.02万
• 依托单位: STANFORD UNIVERSITY
• 依托单位国家: 美国
• 财政年份: 2006
• 资助国家: 美国
• 起止时间: 2006-03-01 至 2007-02-28
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7370691
• 关键词: STRUCTURE; BASED; DEVELOPMENT; INHIBITORS; VIRAL

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. The viral chymotrypsin-like proteases of positive-sense, single-stranded RNA viruses are an ideal target for the design of antiviral drugs. The enzymes have a unique mechanism and most have a cleavage specificity that is different from that of all known mammalian proteases. The viral proteases are also absolutely required for viral replication. Many important pathogens of humans and animals belong to this group of viruses. We and others have determined crystal structures of a number of viral chymotrypsin-like proteases, including some with bound inhibitors. This work is valuable for the understanding of viral evolution, enzymatic mechanisms and the development of anti viral drugs. We are pursuing a project to develop different and more effective inhibitors of several different viral proteases.

本子项目是利用由NIH/NCRR资助的中心赠款提供的资源的众多研究子项目之一。子项目和研究者（PI）可能已经从另一个NIH来源获得了主要资金，因此可以在其他CRISP条目中表示。列出的机构是中心的，不一定是研究者的机构。正意义单链RNA病毒的病毒凝乳胰蛋白酶样蛋白酶是设计抗病毒药物的理想靶点。这些酶具有独特的机制，并且大多数具有与所有已知哺乳动物蛋白酶不同的切割特异性。病毒蛋白酶也是病毒复制所必需的。人类和动物的许多重要病原体都属于这类病毒。我们和其他人已经确定了许多病毒凝乳胰蛋白酶样蛋白酶的晶体结构，包括一些结合抑制剂。这项工作对了解病毒进化、酶促机制和开发抗病毒药物具有重要意义。我们正在进行一个项目，开发几种不同的病毒蛋白酶的不同和更有效的抑制剂。